One To Watch

Cabaletta Bio

A clinical-stage biotechnology company developing curative CAR-T cell therapies targeting B cell-mediated autoimmune diseases, with a pipeline spanning pemphigus, myasthenia gravis, and hemophilia A.

Company Overview

A clinical-stage biotechnology company developing curative CAR-T cell therapies targeting B cell-mediated autoimmune diseases, with a pipeline spanning pemphigus, myasthenia gravis, and hemophilia A. Cabaletta Bio trades on Nasdaq under the ticker CABA and is focused on engineered T cell therapies designed to eliminate the pathogenic B cells driving debilitating autoimmune conditions. The company's ambition is explicitly curative: rather than managing symptoms, its chimeric autoantibody receptor T cell (CAART) platform aims to provide durable disease elimination with a single treatment course.

Headquarters and Global Presence

Cabaletta Bio is headquartered in Philadelphia, Pennsylvania, positioning it close to its founding academic partner, the University of Pennsylvania, a global center of CAR-T cell therapy innovation. The company maintains manufacturing and clinical collaborations that extend its operational reach into the United Kingdom through its partnership with Oxford Biomedica.

Founding and History

Cabaletta Bio was founded by leading experts in autoimmune diseases and CAR-T technology, drawing heavily on research and intellectual property developed at the University of Pennsylvania. The company went public on Nasdaq under the ticker CABA, providing access to capital markets to advance its pipeline into clinical-stage studies. In May 2026, the company priced a $150 million underwritten public offering of 51,725,000 shares of common stock, underscoring sustained investor confidence in its curative autoimmune thesis.

Therapy Areas and Focus

Cabaletta Bio is focused exclusively on B cell-mediated autoimmune diseases — conditions in which self-reactive B cells and the autoantibodies they produce cause tissue destruction. Its pipeline targets pemphigus vulgaris, pemphigus foliaceus, muscle-specific kinase myasthenia gravis (MuSK-MG), and hemophilia A with inhibitors, all conditions defined by specific, well-characterized autoantibodies. These diseases share a common immunological driver — aberrant B cell activity — making them well-suited to the company's precision cell therapy strategy.

Technology Platforms and Modalities

Cabaletta's proprietary CAART (chimeric autoantibody receptor T cell) platform engineers autologous T cells to express the specific autoantigen recognized by pathogenic B cells, allowing them to selectively eliminate the disease-causing B cell populations while preserving normal immune function. This precision targeting distinguishes CAART from conventional CAR-T approaches, which broadly deplete B cells and carry significant immunosuppression risk. The platform is designed to be curative in a single administration, addressing a critical unmet need in chronic autoimmune care. The technology was originally developed at the University of Pennsylvania, providing a robust scientific foundation for clinical translation.

Key Pipeline and Programs

Resecabtagene autoleucel (rese-cel), formerly designated DSG3-CAART, is the company's lead asset — an autologous CAART therapy targeting desmoglein-3-specific B cells in patients with pemphigus vulgaris (PV), a life-threatening blistering skin disease. Rese-cel is being evaluated in the DesCAARTes clinical trial, which represents the company's pivotal clinical program, and has generated clinical proof-of-concept data establishing disease remission in treated patients.

MuSK-CAART targets muscle-specific kinase autoantibody-producing B cells in patients with MuSK myasthenia gravis, a severe neuromuscular disorder. This program reflects the platform's modular nature — the same CAART engineering approach can be redirected to different autoantigen targets. DSG3/1-CAART is a dual-targeting construct designed to address pemphigus foliaceus and mixed pemphigus subtypes driven by both desmoglein-3 and desmoglein-1 autoantibodies. FVIII-CAART, developed in collaboration with the University of Pennsylvania, targets factor VIII-specific B cells in hemophilia A patients who develop inhibitory antibodies, extending the platform into hematology.

Recent Developments

In May 2026, Cabaletta Bio priced a significant $150 million public offering, signaling a capital raise consistent with advancing programs toward later-stage milestones. In June 2024, Oxford Biomedica announced an expansion of its license and supply agreement with Cabaletta, deepening the manufacturing partnership critical to scaling autologous cell therapy production. The company also expanded its executive leadership team with the appointment of Samik Basu, M.D. as Chief Scientific Officer and Heather Harte-Hall, MSc. as Chief Compliance Officer, strengthening its operational infrastructure for late-stage development.

Key Personnel

David Chang, M.D., Ph.D., serves as President and Chief Executive Officer, bringing clinical and scientific expertise in cell therapy and autoimmune disease development to guide the company's pipeline strategy. Samik Basu, M.D., serves as Chief Scientific Officer, appointed to lead the scientific and translational research functions as the company's platform expands. The leadership team is further described as comprising physicians, scientists, and pharmaceutical industry veterans with direct experience in novel cell therapy development and commercialization.

Strategic Partnerships

Cabaletta Bio's foundational scientific collaboration with the University of Pennsylvania underpins multiple pipeline programs, including the FVIII-CAART asset developed jointly with Penn researchers. On the manufacturing side, Oxford Biomedica serves as a key license and supply partner — a relationship expanded in June 2024 — providing the viral vector manufacturing capabilities essential for autologous CAR-T production at scale. These partnerships combine academic scientific depth with commercial-grade manufacturing infrastructure.

FAQ Section

Cabaletta is built on the premise that B cell-mediated autoimmune diseases share a common, targetable immunological driver — the pathogenic autoantibody-producing B cell — making them ideal for precision cell therapy. By focusing exclusively on this disease class, the company can apply the same CAART engineering platform across multiple indications, generating pipeline breadth from a single technological foundation. The goal is curative treatment with a single administration, a fundamentally different value proposition than chronic immunosuppressive therapy.

Conventional CAR-T therapies in oncology typically target pan-B cell markers like CD19, resulting in broad B cell depletion and significant immunosuppression. Cabaletta's CAART approach instead arms T cells with the specific autoantigen recognized by pathogenic B cells — for example, desmoglein-3 in pemphigus vulgaris — so that only the disease-causing B cell clone is eliminated. This selectivity is intended to ablate pathological immunity while preserving the broader immune repertoire, reducing the immunosuppressive burden that limits conventional CAR-T use in non-oncology settings.

Current standard-of-care for pemphigus vulgaris includes rituximab and long-term corticosteroids, which manage but rarely cure the disease, leaving patients exposed to chronic immunosuppression risks. Resecabtagene autoleucel targets only DSG3-specific B cells, the precise population responsible for the autoantibody production that drives blister formation. Early clinical data from the DesCAARTes trial have demonstrated disease remission in treated patients, suggesting the potential for durable, treatment-free outcomes unachievable with existing agents.

DesCAARTes is Cabaletta Bio's pivotal clinical trial evaluating resecabtagene autoleucel in patients with pemphigus vulgaris, designed to generate the efficacy and safety data required to support regulatory submissions. The trial has produced clinical proof-of-concept, with treated patients achieving disease remission — a landmark result for a condition historically managed with ongoing immunosuppression. These results have been central to the company's investor narrative and supported its ability to raise $150 million in a public offering in May 2026.

Beyond pemphigus vulgaris and foliaceus, Cabaletta's pipeline extends into neuromuscular disease through MuSK-CAART for muscle-specific kinase myasthenia gravis, and into hematology through FVIII-CAART for hemophilia A patients who develop inhibitory antibodies against factor VIII. This breadth demonstrates the modularity of the CAART platform — the same engineering approach redirected to different autoantigen targets across distinct disease categories. All indications share the unifying biology of pathogenic autoantibody-secreting B cells as the primary disease driver.

Cabaletta is a clinical-stage company with its lead asset, resecabtagene autoleucel, the most advanced in the pipeline following proof-of-concept data generated in the DesCAARTes trial. The $150 million public offering completed in May 2026 provides capital runway to advance resecabtagene autoleucel toward later-stage milestones and to progress earlier programs including MuSK-CAART and DSG3/1-CAART into and through Phase I studies. The company's expanded partnership with Oxford Biomedica for manufacturing scale-up is a key operational readiness milestone ahead of potential registration-enabling trials.

Cabaletta is at a pivotal juncture, with several near-term events likely to define its trajectory. Key watchpoints include:

Clinical data readouts from the DesCAARTes trial for resecabtagene autoleucel, which will determine the path to regulatory submission and potential approval.
Manufacturing scale-up execution with Oxford Biomedica, given that autologous CAR-T production reliability is a critical commercial bottleneck.
Advancement of MuSK-CAART and DSG3/1-CAART into or through Phase I, which would validate the platform's modularity across additional indications.
Deployment of the $150 million raised in May 2026 and the timeline to next financing needs, as clinical-stage biotechs face ongoing capital burn risk.
Competitive dynamics as broader interest in CAR-T approaches for autoimmune diseases intensifies, with multiple entrants pursuing similar disease areas.

Want to Update your Company's Profile?